Pages that link to "Q33756662"
Jump to navigation
Jump to search
The following pages link to Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen (Q33756662):
Displaying 50 items.
- Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? (Q26740601) (← links)
- A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment (Q26749571) (← links)
- Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances (Q26827475) (← links)
- Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy (Q26851608) (← links)
- Immunotherapy for prostate cancer: recent developments and future challenges (Q26852388) (← links)
- From bench to bedside: immunotherapy for prostate cancer (Q26864390) (← links)
- Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation (Q28655545) (← links)
- Immunosuppressive strategies that are mediated by tumor cells (Q29636247) (← links)
- Age-dependent tolerance to an endogenous tumor-associated antigen (Q30439993) (← links)
- iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells (Q33523809) (← links)
- Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications (Q33621393) (← links)
- Preclinical and clinical development of DNA vaccines for prostate cancer (Q33740811) (← links)
- Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. (Q33756652) (← links)
- Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation (Q33756678) (← links)
- Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen (Q33791226) (← links)
- Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses (Q33798326) (← links)
- The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells (Q33802637) (← links)
- In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice (Q33837085) (← links)
- Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice (Q33872776) (← links)
- Shaping the repertoire of tumor-infiltrating effector and regulatory T cells (Q34003592) (← links)
- Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer (Q34321844) (← links)
- Exploiting synergy: immune-based combinations in the treatment of prostate cancer (Q34687216) (← links)
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems (Q34700552) (← links)
- Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression (Q34755544) (← links)
- Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. (Q34856691) (← links)
- Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells (Q34856800) (← links)
- Prostate cancer as a model for tumour immunotherapy (Q34856875) (← links)
- Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model (Q34887495) (← links)
- New insights into androgenic immune regulation (Q34936575) (← links)
- Proposed mechanisms of action for prostate cancer vaccines. (Q35174754) (← links)
- Anti‐tumor effects of endogenous prostate cancer‐specific CD8 T cells in a murine TCR transgenic model (Q35641792) (← links)
- Prostate cancer immunotherapy (Q35688425) (← links)
- Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer (Q35951653) (← links)
- Combining Vaccines with Conventional Therapies for Cancer (Q36082331) (← links)
- Enhancing efficacy of therapeutic vaccinations by combination with other modalities (Q36113943) (← links)
- Update on Prostate Cancer Vaccines (Q36169608) (← links)
- The Current and Emerging Role of Immunotherapy in Prostate Cancer (Q36249922) (← links)
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer (Q36254081) (← links)
- A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4(+) T cell receptor repertoire clonality (Q36256308) (← links)
- Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer (Q36285594) (← links)
- From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer (Q36293995) (← links)
- Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research (Q36316871) (← links)
- Current perspectives in prostate cancer vaccines (Q36317185) (← links)
- Therapeutic Cancer Vaccine Fulfills the Promise of Immunotherapy in Prostate Cancer (Q36326737) (← links)
- Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy (Q36349514) (← links)
- Cancer vaccines: current directions and perspectives in prostate cancer (Q36368968) (← links)
- SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade (Q36491182) (← links)
- Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. (Q36567448) (← links)
- Immune resistance orchestrated by the tumor microenvironment (Q36593747) (← links)
- Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer (Q36620552) (← links)